Krystal Biotech Announces Positive Clinical Data for New Dermatology Program KB113 Demonstrating Broad Basal Cell Carcinoma Regression in Patients with Gorlin Syndrome

Go back to Krystal Biotech Announces Positive Clinical Data for New Dermatology Program KB113 Demonstrating Broad Basal Cell Carcinoma Regression in Patients with Gorlin Syndrome
(NASDAQ: KRYS) Delayed: 322.17 -3.25 (1%)
Previous Close $325.42    52 Week High $ 
Open $324.31    52 Week Low $ 
Day High $327.35    P/E N/A 
Day Low $319.83    EPS $ 
Volume 468,869